If you have an emerging, cutting-edge technology project based on (or with a link) to the BioRegion of Catalonia and want to launch it to market, submit your proposal by June 15 and train with experts...
Read more Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Vivet Therapeutics (“Vivet”) announced today an agreement whereby Mirum has the exclusive option to develop and subsequently commercialize Viv...
Read moreEsta actuación de colaboración se enmarca en un acuerdo más amplio alcanzado entre CIC bioGUNE y BIOLAN en áreas encaminadas al diagnóstico de enfermedades y otras aplicaciones para la salud.
Read moreSynendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, today annou...
Read moreAdcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The ...
Read moreEl programa destinado a proyectos del sector de la salud ha seleccionado a 3 startups españolas para Bridgehead Global y a 6 para Bridgehead Europe
Read moreLa ganadora del XVI Premi PRBB que reconoce al mejor trabajo de investigación en Ciencias de la Salud y de la Vida es Núria González Cuesta, alumna de segundo de Bachillerato en el Instituto France...
Read moreDos trabajos de investigadores del CIBER-BBN en el Instituto de Microelectrónica de Barcelona del CSIC hacen una revisión de los últimos avances de la tecnología organ-on-chip en la simulación...
Read moreCytoki Pharma ApS, a private biotech company incorporated in Copenhagen, Denmark, today announced a $45 million series A financing led by existing investor Lundbeckfonden Emerge (Denmark) together ...
Read moreNeuroelectrics, a pioneer in brain stimulation technologies and therapies, has raised $17.5M in a Series A financing led by Morningside Ventures. The funds will be used to further develop Neuroelec...
Read moreThe Cilastatin project arose thanks to the research carried out by the deceased Dr. Alberto Tejedor, who was Nephrology Service section chief at the Gregorio Marañón General University Hospital and ...
Read moreThe biopharmaceutical company Ability Pharmaceuticals, SL today announced the inclusion of the first patients in a phase 2b clinical trial with its novel autophagy-inducer anticancer compound ABTL0812...
Read more